Does Dr. KALID ADAB have financial conflicts of interest?

Dr. KALID ADAB (MD) has received a total of $4,244 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $4,244 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. KALID ADAB?

According to CMS Open Payments data, Dr. KALID ADAB received funding from E.R. SQUIBB & SONS, L.L.C ($413), NOVARTIS PHARMACEUTICALS CORPORATION ($400), and MERCK SHARP & DOHME ($352).

Does Dr. KALID ADAB receive research grants or speaking fees?

Dr. KALID ADAB has received $4,244 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. KALID ADAB

MDReal-Time Hydrated

Specialty: Internal Medicine, Hematology & Oncology

Practice Location: MILWAUKEE, WI 53215

NPI Number: 1346473345

LIFETIME INDUSTRY VALUE

$4,244

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ADAB is a verified Internal Medicine, Hematology & Oncology practitioner based in MILWAUKEE, WI.

Between 2021 and 2024, Dr. ADAB had an overall industry promotional and research financial footprint of $4,244 as recorded in the federal CMS Open Payments database.

$4,244 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ADAB's primary funding source is E.R. SQUIBB & SONS, L.L.C, which accounts for $413 (representing 9.7% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

E.R. SQUIBB & SONS, L.L.C

Rank 1

$413

9.7%

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 2

$400

9.4%

MERCK SHARP & DOHME

Rank 3

$352

8.3%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.